These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26487967)

  • 1. Development of targeted therapies in treatment of glioblastoma.
    Xu YY; Gao P; Sun Y; Duan YR
    Cancer Biol Med; 2015 Sep; 12(3):223-37. PubMed ID: 26487967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of receptor tyrosine kinases and their ligands in glioblastoma.
    Carrasco-García E; Saceda M; Martínez-Lacaci I
    Cells; 2014 Apr; 3(2):199-235. PubMed ID: 24709958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
    Mattei V; Santilli F; Martellucci S; Delle Monache S; Fabrizi J; Colapietro A; Angelucci A; Festuccia C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.
    Martins C; Sarmento B
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Glioblastoma Therapy: An Update on Current Approaches.
    Angom RS; Nakka NMR; Bhattacharya S
    Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapy: A new avenue in glioblastoma treatment.
    El Atat O; Naser R; Abdelkhalek M; Habib RA; El Sibai M
    Oncol Lett; 2023 Feb; 25(2):46. PubMed ID: 36644133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma.
    Habeeb M; Vengateswaran HT; You HW; Saddhono K; Aher KB; Bhavar GB
    J Mater Chem B; 2024 Feb; 12(7):1677-1705. PubMed ID: 38288615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
    Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
    Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standards of care and novel approaches in the management of glioblastoma multiforme.
    Hottinger AF; Stupp R; Homicsko K
    Chin J Cancer; 2014 Jan; 33(1):32-9. PubMed ID: 24384238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ
    J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
    Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
    Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
    Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
    Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier.
    Sharma RK; Calderon C; Vivas-Mejia PE
    Front Med Technol; 2021; 3():678593. PubMed ID: 35047931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.
    Srivastava R; Dodda M; Zou H; Li X; Hu B
    Antioxid Redox Signal; 2023 Nov; 39(13-15):904-922. PubMed ID: 37166370
    [No Abstract]   [Full Text] [Related]  

  • 20. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.